MRP Capital Investments LLC Has $494,000 Stock Holdings in Pfizer Inc. $PFE

by · The Markets Daily

MRP Capital Investments LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3,980.0% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 20,400 shares of the biopharmaceutical company’s stock after buying an additional 19,900 shares during the period. MRP Capital Investments LLC’s holdings in Pfizer were worth $494,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Westbourne Investments Inc. bought a new stake in shares of Pfizer in the 1st quarter valued at about $2,411,000. Bourne Lent Asset Management Inc. grew its holdings in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. Ossiam increased its stake in Pfizer by 71.2% in the second quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock valued at $136,970,000 after purchasing an additional 2,349,058 shares in the last quarter. Strs Ohio acquired a new stake in Pfizer in the first quarter worth $49,968,000. Finally, IFM Investors Pty Ltd boosted its position in shares of Pfizer by 3.8% during the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after purchasing an additional 41,263 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

Shares of Pfizer stock opened at $25.86 on Friday. The firm has a market cap of $147.04 billion, a PE ratio of 15.04 and a beta of 0.46. The business’s 50 day simple moving average is $25.12 and its 200 day simple moving average is $24.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 7th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date was Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Analyst Ratings Changes

A number of research firms recently commented on PFE. Citigroup began coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Scotiabank began coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. HSBC reissued a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.33.

View Our Latest Research Report on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).